Charles Mcwherter Biography and Net Worth

Dr. Charles A. McWherter, PhD, most recently served as Chief Scientific Officer at CymaBay Therapeutics, Inc. since 2013 and served as its President of Research and Development since November 2022 until its acquisition by Gilead Sciences in March 2024. Dr. McWherter served as Senior Vice President of Research and Preclinical Development at CymaBay Therapeutics from August 2007 to November 2013. From 2003 to 2007, Dr. McWherter served as Vice President and Head of Pfizer, Inc.'s cardiovascular research unit in St. Louis during which his organization built a portfolio of clinical candidates for hypertension, renal disease, and thrombosis. Prior to Pfizer, Inc. he served as Vice President of Drug Discovery at Sugen Inc., where he developed and implemented a strategic plan integrating structure-based drug design with advanced compound screening. Before joining Sugen, Dr. McWherter worked at Pharmacia Corp. and its predecessor companies, G.D. Searle & Co. and Monsanto Co., for almost two decades, rising to the position of Director for oncology research. He has also served as Chairman of the Board of Directors of the Greater St. Louis Division of the American Heart Association. Dr. McWherter has published more than 45 scientific articles and holds many U.S. patents. He previously served as an adjunct assistant professor of molecular biology and pharmacology at the Washington University School of Medicine.

What is Charles Mcwherter's net worth?

The estimated net worth of Charles Mcwherter is at least $222.60 thousand as of January 21st, 2025. Mcwherter owns 15,000 shares of 89BIO stock worth more than $222,600 as of December 5th. This net worth approximation does not reflect any other investments that Mcwherter may own. Learn More about Charles Mcwherter's net worth.

How do I contact Charles Mcwherter?

The corporate mailing address for Mcwherter and other 89BIO executives is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. 89BIO can also be reached via phone at 415-432-9270 and via email at [email protected]. Learn More on Charles Mcwherter's contact information.

Has Charles Mcwherter been buying or selling shares of 89BIO?

Charles Mcwherter has not been actively trading shares of 89BIO within the last three months. Most recently, on Tuesday, January 21st, Charles Mcwherter bought 5,000 shares of 89BIO stock. The stock was acquired at an average cost of $6.55 per share, with a total value of $32,750.00. Following the completion of the transaction, the director now directly owns 15,000 shares of the company's stock, valued at $98,250. Learn More on Charles Mcwherter's trading history.

Who are 89BIO's active insiders?

89BIO's insider roster includes Gregory Grunberg (Director), Michael Hayden (Director), Morrow III (Director), Kathleen Laporte (Director), Quoc Le-Nguyen (Insider), Ryan Martins (CFO), Charles Mcwherter (Director), Rohan Palekar (CEO), Ollin Sykes (Director), and Ram Waisbourd (Insider). Learn More on 89BIO's active insiders.

Are insiders buying or selling shares of 89BIO?

In the last twelve months, 89BIO insiders bought shares 4 times. They purchased a total of 5,734,285 shares worth more than $50,152,193.75. In the last twelve months, insiders at the sold shares 3 times. They sold a total of 36,753 shares worth more than $277,637.64. The most recent insider tranaction occured on July, 15th when insider Quoc Le-Nguyen sold 10,461 shares worth more than $115,280.22. Insiders at 89BIO own 2.6% of the company. Learn More about insider trades at 89BIO.

Information on this page was last updated on 7/15/2025.